SoVarGen Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $17.2M

  • Investors
  • 22

SoVarGen General Information

Description

Developer of novel therapeutics and diagnostics designed to treat intractable central nervous system (CNS) diseases caused by low-level somatic mutation. The company provides differentiated research and development methods and resources to overcome the limitations of existing brain disease treatment development and present a new paradigm for developing treatments, enabling patients to get effective therapies in less time.

Contact Information

Website
sovargen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building Number 2, KAIST Munji Campus
  • 193 Munji-ro, Yuseong-gu, Daejeon
  • Daejeon, Yuseong 34051
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Building Number 2, KAIST Munji Campus
  • 193 Munji-ro, Yuseong-gu, Daejeon
  • Daejeon, Yuseong 34051
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SoVarGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 03-Jul-2025 $17.2M Completed Generating Revenue
5. Early Stage VC 01-Jul-2022 Completed Generating Revenue
4. Secondary Transaction - Private 01-Jun-2022 Completed Generating Revenue
3. Early Stage VC (Series B) 03-Sep-2020 Completed Generating Revenue
2. Early Stage VC (Series A) 01-Sep-2018 $8.91M $8.91M Completed Startup
1. Accelerator/Incubator 01-Jan-2018 Completed Startup
To view SoVarGen’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

SoVarGen Patents

  • 18

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

SoVarGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026079788-A1 Compound for regulating activity or expression of braf and uses therof Pending 08-Oct-2024
WO-2026010401-A1 Animal model with idh mutant glioma and use thereof Pending 04-Jul-2024
AU-2025214952-A1 Compound for regulating activity or expression of mtor and use therof Pending 30-Jan-2024
WO-2025165154-A1 Compound for regulating activity or expression of mtor and use therof Pending 30-Jan-2024
WO-2025014256-A1 Composition for regulating activity or expression of gap43 Inactive 10-Jul-2023 C12N15/113
To view SoVarGen’s complete patent history, request access »

SoVarGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SoVarGen Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
A-Stone Ventures Venture Capital Minority
CKD Venture Capital Corporate Venture Capital
Dongkuk Holdings Company Corporation
DSC Investment Venture Capital Minority
Industrial Bank of Korea PE/Buyout
You’re viewing 5 of 22 investors. Get the full list »

Ready to get started?

Request a free trial

SoVarGen FAQs

  • When was SoVarGen founded?

    SoVarGen was founded in 2018.

  • Where is SoVarGen headquartered?

    SoVarGen is headquartered in Daejeon, South Korea.

  • What is the size of SoVarGen?

    SoVarGen has 31 total employees.

  • What industry is SoVarGen in?

    SoVarGen’s primary industry is Drug Discovery.

  • Is SoVarGen a private or public company?

    SoVarGen is a Private company.

  • What is SoVarGen’s current revenue?

    The current revenue for SoVarGen is .

  • How much funding has SoVarGen raised over time?

    SoVarGen has raised $55.6M.

  • Who are SoVarGen’s investors?

    A-Stone Ventures, CKD Venture Capital, Dongkuk Holdings Company, DSC Investment, and Industrial Bank of Korea are 5 of 22 investors who have invested in SoVarGen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process